DELPHINE REA (PARIS)
ALLOGENEIC STEM CELL TRANSPLANTATION SHOULD BE CONSIDERED THIRD
LINE OPTION IN CHRONIC PHASE CML – NO
CML patients who need a 3rd line treatment are heterogeneous in terms of type of prior TKI
exposure, reasons for treatment change, presence or absence of BCR-ABL1 KD mutations.
Their management represent a challenge and there is no overall single best strategy.
Allogeneic stem cell transplantation (SCT) may be considered, however in some patients,
sequential use of TKI may offer a chance for acceptable responses and favorable long-term
outcome. Novel compounds are under development and participation to trials may be
encouraged especially when allo SCT is not feasible.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES